arrow
R

Rahul A. Sheth

ut md anderson cancer center
H指数:36
被引数:4,111

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Stereotactic Percutaneous Thermal Ablation of Primary and Metastatic Liver Tumors: A Prospective Registry-Based Study

立体定向经皮热消融治疗原发性及转移性肝癌:一项前瞻性登记研究

2026-05-180
PRE
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence

纳武利尤单抗联合伊匹木单抗诱导肾髓质癌发生超进展:一项II期试验结果及临床前证据

2025-11-250
OAAI
Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profiling

通过整合基因组学和转录组学分析鉴定肾髓质癌的治疗靶点

2025-10-300
OAAI
20Phase II trial of ivonescimab in patients with advanced clear cell renal cell carcinoma previously treated with immune checkpoint blockade: IVORY trial (NCT06940518)

II期临床试验:评估ivonescimab在既往接受过免疫检查点阻断治疗的晚期透明细胞肾细胞癌患者中的疗效(IVORY试验,NCT06940518)。

2025-10-010
OAAI
Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors

BMS-986299的I期研究,BMS-986299是一种NLRP3激动剂,作为单药治疗以及与nivolumab和ipilimumab联合用于晚期实体瘤患者的治疗。

2025-01-161
OA
Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis

腹膜内ipilimumab和nivolumab在患有腹膜癌病的复发性妇科恶性肿瘤患者中的1b期研究

MED
IF11.8
2024-04-015
PRE
Hyperprogression due to myeloid mimicry in renal medullary carcinoma treated with nivolumab plus ipilimumab
2024-03-220
PRE